Report of foreign issuer [Rules 13a-16 and 15d-16]

Shareholders' Equity (Tables)

v3.25.2
Shareholders' Equity (Tables)
6 Months Ended
Jun. 30, 2025
Shareholders' Equity [Abstract]  
Schedule of Fair value of Company’s Share Options Granted

The fair value of the Company’s share options granted was estimated using the binomial option pricing model using the following range assumptions:

 

Description   Six months ended
June 30, 2025
 
       
Risk-free interest rate     4.21 – 4.04 %
Expected volatility     79.56- 79.82 %
Dividend yield     0  
Contractual life     10  
Early Exercise Multiple (Suboptimal Factor)     2.5  
Exercise price (NIS)     0.018-0.013  
Schedule of Company's Option Activity

The following table summarizes the Company’s options activity during the six months ended June 30, 2025: 

 

    Number of
options
    Weighted
average
exercise
price
    Weighted
average
remaining
contractual
terms (in years)
    Aggregate intrinsic
value
    weighted
average of
the grant
date fair
value
 
                               
Outstanding at December 31, 2024     124,829,000     $ 0.03       7.1      
-
     
-
 
Grants     24,000,000     $ 0.01       10       -     $ 0.00  
Expired     (30,000 )    
-
     
-
      -       -  
                                         
Outstanding at June 30, 2025     148,799,000     $ 0.03       7.1      
-
     
-
 
                                         
Vested and expected to vest at June 30, 2025     148,799,000     $ 0.03       7.1      
-
     
-
 
                                         
Exercisable at June 30, 2025     60,283,375     $ 0.06       5.8      
-
     
-
 
Schedule of Expenses Recognized Financial Statements

Share based expenses recognized in the financial statements:

 

    Six months ended
June 30
 
    2025     2024  
             
Research and development   $ 30     $ 34  
General and administrative (*)     221       159  
                 
    $ 251     $ 193  

 

(*) Included $141 and $113 value of shares issued to Company’s service provider for the six month ended June 30, 2025 and 2024, respectively. see also Note 5(3).
Schedule of Information Regarding Outstanding Warrants to Purchase Shares

The following table summarizes information regarding outstanding warrants to purchase the Company’s ordinary shares as of June 30, 2025:

 

             
Issuance date   Number of
outstanding
Warrants
    Exercise
price per
warrant
 
             
January 2020     23,838,038     $ 0.12  
December 2021     10,500,000     $ 0.07  
January 2023     28,636,500     $ 0.02  
November 2023     771,366,900     $ 0.00  
August 2024     1,774,285,800     $ 0.01  
April 2025     52,500,000     $ 0.01  
                 
      2,661,127,238